Details:
Genexine’s, GX-H9, a proprietary long-acting growth hormone shows positive topline results from phase 3 study for growth hormone deficiency, is being conducted in China with I-Mab.
Lead Product(s): Eftansomatropin Alfa
Therapeutic Area: Endocrinology Product Name: GX-H9
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: I-Mab Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
DWP16001 (enavogliflozin) is a new diabetes drug in the SGLT-2 inhibitor class. The two combination trials, Enavogliflozin-Metformin and Enavogliflozin-Metformin-Gemigliptin combination, demonstrated non-inferiority in HbAc1 change compared to dapagliflozin 10 mg.
Lead Product(s): Enavogliflozin,Metformin,Gemigliptin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Enavogliflozin is an SGLT-2 inhibitor for diabetes in development by Daewoong for the first time in South Korea. The safety of Enavogliflozin has been proven through three sequential clinical trials of monotherapy, metformin combination, and Metformin-Gemigliptin combination.
Lead Product(s): Enavogliflozin,Metformin,Gemigliptin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2022
Details:
In the study, researchers compared fructosamine, fasting glucose, and insulin dose changes in a group treated with insulin and Enavogliflozin once daily for eight weeks and the other group once every three days to evaluate its weight and blood pressure.
Lead Product(s): Enavogliflozin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021